Objective:
To analyze the effects of aflibercept 8 mg on visual outcomes and injection intervals in patients with wet AMD and DME using the IRIS registry.
Key Findings:
- Treatment-naïve patients achieved an injection interval of 12 weeks after 6 months.
- Treatment-naïve patients gained 4 letters of vision in the AMD population and 5 letters in the DME population.
- Treatment-experienced patients extended their injection interval by an additional 2 weeks while maintaining vision.
Interpretation:
The findings indicate that aflibercept 8 mg provides significant benefits in visual acuity and injection frequency for both treatment-naïve and treatment-experienced patients.
Limitations:
- The study is observational and may be subject to confounding factors.
- Long-term outcomes beyond one year were not assessed.
Conclusion:
Aflibercept 8 mg demonstrates improved visual outcomes and longer injection intervals, making it a promising treatment option for patients with wet AMD and DME.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
